SUO 2024: BOND-003 Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Presented by Mark Tyson II, MD, MPH
The 2024 SUO annual meeting included a urothelial carcinoma session, featuring a presentation by Dr. Mark Tyson discussing BOND-003 Cohort P, a multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high-risk, papillary only, BCG-unresponsive non muscle invasive bladder cancer (NMIBC).
Read More
SCS AUA 2024: Emerging Treatments for NMIBC
Presented by Neema Navai, MD
The 2024 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation by Dr. Neema Navai discussing emerging treatments for non muscle invasive bladder cancer (NMIBC). From a historical perspective, Dr. Navai notes that Dr. Raymond Pearl performed a case control autopsy study (controlling for sex, age, and race) in 1929 assessing the rate of tuberculosis, finding that in cancer patients it was 6.6% compared to 16.3% in non-cancer patients.
Read More
AUA 2024: BOND-003- Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Presented by Mark Tyson II, MD, MPH
The 2024 American Urological Association (AUA) annual meeting featured a session on bladder cancer trials in progress, and a presentation by Dr. Mark Tyson discussing BOND-003- Cohort P, a multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer.
Read More
AUA 2024: Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Presented by Mark Tyson II, MD, MPH
The 2024 American Urological Association (AUA) annual meeting featured a plenary session, and a presentation by Dr. Mark Tyson discussing results from BOND-003, a phase 3, single-arm study assessing intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer.
Read More
